The SELECT cardiovascular outcomes trial (N=17,604), published in NEJM 2023 (DOI: 10.1056/NEJMoa2307563), demonstrated a 20% reduction in major adverse cardiovascular events (MACE) -- the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke -- in overweight or obese adults without diabetes
In addition, B12 and appetite control go hand-in-hand
Exposure to di-2-ethylhexyl phthalate and breast neoplasm incidence: A cohort study
Individuals with autoimmune conditions or immunosuppression should exercise caution, as IGF-1s immune-modulating effects could theoretically exacerbate existing conditions
Why Choose IGF-1 LR3 at Esthetic Solutions
Quality, testing and Canadian shipping Every research compound in this category is produced in a cGMP-compliant facility and independently verified by third-party HPLC to at least 99% purity, with a certificate of analysis available on request